Research analysts at Maxim Group began coverage on shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) in a note issued to investors on Monday. The brokerage set a “buy” rating and a $14.00 price target on the specialty pharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 35.27% from the stock’s previous close.

The analysts wrote, “SciClone is a US-based specialty pharma company with its operating focus on the China pharmaceuticals market.””

Shares of SciClone Pharmaceuticals (NASDAQ:SCLN) opened at 10.25 on Monday. The firm’s 50-day moving average is $9.76 and its 200 day moving average is $11.20. SciClone Pharmaceuticals has a 52-week low of $7.36 and a 52-week high of $15.02. The company has a market capitalization of $523.29 million, a price-to-earnings ratio of 14.64 and a beta of 1.65.

TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and republished in violation of United States and international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/28/sciclone-pharmaceuticals-inc-scln-given-buy-rating-at-maxim-group.html.

In other news, CEO Friedhelm Blobel sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $10.27, for a total transaction of $308,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Wilson Wai-Shun Cheung sold 149,962 shares of the firm’s stock in a transaction that occurred on Wednesday, October 26th. The stock was sold at an average price of $10.00, for a total transaction of $1,499,620.00. Following the sale, the chief financial officer now directly owns 15,064 shares of the company’s stock, valued at approximately $150,640. The disclosure for this sale can be found here. Insiders own 7.63% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Fox Run Management L.L.C. bought a new stake in shares of SciClone Pharmaceuticals during the second quarter valued at approximately $180,000. Ameriprise Financial Inc. bought a new stake in shares of SciClone Pharmaceuticals during the second quarter valued at approximately $3,130,000. Principal Financial Group Inc. bought a new stake in shares of SciClone Pharmaceuticals during the second quarter valued at approximately $4,587,000. Virginia Retirement Systems ET AL bought a new stake in shares of SciClone Pharmaceuticals during the second quarter valued at approximately $316,000. Finally, Prudential Financial Inc. increased its stake in shares of SciClone Pharmaceuticals by 150.4% in the second quarter. Prudential Financial Inc. now owns 185,317 shares of the specialty pharmaceutical company’s stock valued at $2,420,000 after buying an additional 111,300 shares during the period. 75.68% of the stock is owned by institutional investors.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

5 Day Chart for NASDAQ:SCLN

Receive News & Stock Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.